Aegerion Pharmaceuticals (AEGR)
Aegerion Pharmaceuticals Cash and ST Investments: 63.51M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
AEGR Cash and ST Investments Rankings
| Overall | 44th percentile | 2418 of 4365 |
| Sector | 53rd percentile | 235 of 504 in Healthcare |
| Industry | 43rd percentile | 14 of 25 in Drug Manufacturers - Major |
AEGR Cash and ST Investments Range, Past 5 Years
| Minimum | 0.4079M | Sep 2010 |
| Maximum | 87.54M | Jun 2011 |
| Average | 56.92M |
About Cash and Short Term Investments
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities
Learn More
You may also be interested in these AEGR related companies
AEGR News
Correction - Needham & Company initiates coverage on Aastrom Biosciences (ASTM) at 'Buy'
May 22, 7:17AM Street Insider
May 22, 7:17AM Street Insider
Listen to $AEGR Aegerion Pharmaceuticals Inc at Deutsche Bank AG Health Care Con - live at 10:40 AM, ondemand after - http://stks.co/3hTq
about 20 days ago by earningscast
about 20 days ago by earningscast
Listen to $AEGR Q1 2012 earnings call - live at 08:30 AM, ondemand after - http://stks.co/3b6B
about 26 days ago by earningscast
about 26 days ago by earningscast
Aegerion Pharmaceuticals Announces First Quarter 2012 Financial Results
May 01, 7:00AM GlobeNewswire
May 01, 7:00AM GlobeNewswire
http://stks.co/3at7 Earnings before market open: $ABH, $AGCO, $AEGR, $ACI
about 26 days ago by freefdawatchlistcom
about 26 days ago by freefdawatchlistcom
Aegerion Pharmaceuticals Announces FDA Acceptance of New Drug Application for Review
Apr 30, 8:00AM GlobeNewswire
Apr 30, 8:00AM GlobeNewswire
Aegerion Pharmaceuticals to Announce First Quarter 2012 Financial Results on Tuesday, May 1
Apr 24, 8:00AM GlobeNewswire
Apr 24, 8:00AM GlobeNewswire
A Forward Look, the Year Ahead -- Featured Research on Pfizer Inc. and Aegerion Pharmaceuticals, Inc.
Apr 23, 9:00AM Marketwire
Apr 23, 9:00AM Marketwire
$AEGR forms bearish "Top Triangle" chart pattern. http://stks.co/3IOO
about 46 days ago by RecogniaEvents
about 46 days ago by RecogniaEvents
$AEGR forms bearish "Symmetrical Continuation Triangle" chart pattern. http://stks.co/3IOM
about 46 days ago by RecogniaEvents
about 46 days ago by RecogniaEvents
Aegerion Pharmaceuticals to Present at the Needham Healthcare Conference
Mar 28, 8:00AM GlobeNewswire
Mar 28, 8:00AM GlobeNewswire
Aegerion Pharmaceuticals Announces EMA Acceptance for Review of Marketing Authorization Application for Lomitapide
Mar 20, 7:00AM GlobeNewswire
Mar 20, 7:00AM GlobeNewswire
Aegerion (AEGR) Comments on FDA Review of Lomitapide NDA; Comfortable with Standard Review Classification
Mar 08, 9:21AM Street Insider
Mar 08, 9:21AM Street Insider
Aegerion Pharmaceuticals Comments on Standard Review Classification for Lomitapide NDA
Mar 08, 9:21AM Benzinga
Mar 08, 9:21AM Benzinga
Listen to $AEGR Q4 2011 earnings call - live at 08:30 AM, ondemand after - http://stks.co/2giA
about 82 days ago by earningscast
about 82 days ago by earningscast
Aegerion Pharmaceuticals Announces Fourth-Quarter and Full-Year 2011 Financial Results
Mar 06, 7:00AM GlobeNewswire
Mar 06, 7:00AM GlobeNewswire
Aegerion Pharma (AEGR) Posts Q4 Loss of 66c/Share; Guides FY12 Cash Burn
Mar 06, 6:56AM Street Insider
Mar 06, 6:56AM Street Insider
Aegerion Pharmaceuticals Submits Marketing Applications for Lomitapide in U.S. and EU
Mar 05, 7:02AM Benzinga
Mar 05, 7:02AM Benzinga
Aegerion Pharmaceuticals to Announce Fourth-Quarter and Full-Year 2011 Financial Results on Tuesday, March 6
Feb 27, 8:00AM GlobeNewswire
Feb 27, 8:00AM GlobeNewswire
Aegerion Pharmaceuticals to Present at the Citi 2012 Global Healthcare Conference
Feb 22, 8:00AM GlobeNewswire
Feb 22, 8:00AM GlobeNewswire
Aegerion Pharmaceuticals Announces Webcast of Investor Presentations at Upcoming Conferences
Feb 09, 8:00AM GlobeNewswire
Feb 09, 8:00AM GlobeNewswire
$AEGR Insider Sale: $1.3M of stock sold by Ahls Iii Gp Limited Partnership between January 27, 2012 - January 31, 2012 http://stks.co/2BAp
about 116 days ago by MarketBrief
about 116 days ago by MarketBrief
$AEGR Insider Sale: $1.3M of stock sold by Advent International LLC between January 27, 2012 - January 31, 2012 http://stks.co/2BAm
about 116 days ago by MarketBrief
about 116 days ago by MarketBrief
$AEGR Insider Sale: $1.3M of stock sold by Advent International Corp/ma between January 27, 2012 - January 31, 2012 http://stks.co/2BAk
about 116 days ago by MarketBrief
about 116 days ago by MarketBrief
Aegerion (AEGR) Says Efficacy, Safety Profile for Lomitapide Maintained
Jan 06, 1:00PM Street Insider
Jan 06, 1:00PM Street Insider
Sandford D. Smith Appointed to Aegerion Pharmaceuticals' Board of Directors
Dec 20, 8:00AM GlobeNewswire
Dec 20, 8:00AM GlobeNewswire
Canaccord Genuity Reiterates a 'Buy' on Aegerion Pharmaceuticals (AEGR); Lomitapide Potential as Best-in-Class
Dec 16, 9:00AM Street Insider
Dec 16, 9:00AM Street Insider
$AEGR it's all about homozygous familial cholesterolemia baby... and the potential for broader applications of course.
about 193 days ago by tickertutor
about 193 days ago by tickertutor
$AEGR $15.75 AHLS III GP LIMITED PARTNERSHI other S 120,928 @ $14.61 amnt $1,766,600 proc'd ($137,858) 6/29/2011
about 331 days ago by canarionyc
about 331 days ago by canarionyc
$AEGR $15.75 ADVENT HEALTHCARE & LIFE SCIEN other S 49,005 @ $14.61 amnt $715,899 proc'd ($55,866) 6/29/2011
about 331 days ago by canarionyc
about 331 days ago by canarionyc
$AEGR $15.75 Advent Partners HLS III Limite other S 73,272 @ $14.61 amnt $1,070,407 proc'd ($83,530) 6/29/2011
about 331 days ago by canarionyc
about 331 days ago by canarionyc
IV post & cc link: FDA says that neither $ISIS nor $AEGR will get Fast Track based on LDL endpoint data (only granted for clinical outcomes)
about 345 days ago by BioDueDiligence
about 345 days ago by BioDueDiligence
Aegerion Pharma Files 3.25M-Share Stock Shelf Offering -Dow Jones
$AEGr
about 346 days ago by Benzinga
about 346 days ago by Benzinga
$AEGR $17.56 Beer Marc D CEO P 5,332 @ $18.70 amnt $99,702 proc'd ($6,072) 6/1/2011
about 359 days ago by canarionyc
about 359 days ago by canarionyc
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AEGR | 13.56 | +0.00 | +0.00% | 288.42M |
| AEG | 4.30 | -0.01 | -0.23% | 8.211B |
| ABD | 9.40 | -0.08 | -0.84% | 523.11M |
| ABCO | 94.61 | -1.67 | -1.73% | 1.577B |
| ABCD | 1.36 | +0.08 | +6.25% | 67.40M |
| ABCB | 11.42 | -0.13 | -1.13% | 271.22M |
| ABC | 36.90 | +0.44 | +1.21% | 9.514B |
| ABB | 16.18 | -0.22 | -1.34% | 37.45B |
| ADAT | 0.70 | -0.03 | -3.89% | 37.66M |
| ACY | 11.95 | -0.80 | -6.27% | 18.40M |